% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reschke:301484,
      author       = {R. Reschke$^*$ and J. Hassel$^*$},
      title        = {{T}ebentafusp—the first drug with a significant and
                      persistent survival benefit in metastatic uveal
                      melanoma.[{T}ebentafusp – erstes {M}edikament mit
                      signifikantem und andauerndem Überlebensvorteil beim
                      metastasierten {U}veamelanom.]},
      journal      = {Best Practice Onkologie},
      volume       = {20},
      number       = {5},
      issn         = {0946-4565},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2025-01026},
      pages        = {186 - 189},
      year         = {2025},
      abstract     = {Uveal melanoma, also known as choroidal melanoma, is a rare
                      form of melanoma that arises from pigment cells of the eye,
                      primarily the choroid. It can also affect the iris or the
                      ciliary body and often metastasizes to distant sites,
                      primarily the liver. In contrast to other types of melanoma,
                      uveal melanoma responds poorly to treatment with checkpoint
                      inhibitors; it is thus associated with a worse prognosis.
                      The new immunotherapeutic tebentafusp, however, is a
                      promising treatment option for patients with human leukocyte
                      antigen (HLA) type A*02:01. Tebentafusp is a bispecific
                      protein that specifically recognizes a peptide of the
                      melanocyte differentiation antigen gp100 and activates T
                      cells. This leads to polyclonal activation of T cells in the
                      tumor environment and antitumor immune defense. A phase III
                      trial has shown that tebentafusp significantly improves the
                      overall survival of patients with metastatic uveal melanoma
                      in comparison to other treatments. After 3 years, $27\%$ of
                      tebentafusp-treated patients were still alive, compared to
                      $18\%$ in the control arm. Median overall survival was 21.6
                      months in the tebentafusp group and 16.9 months in the
                      control arm. Adverse effects of tebentafusp treatment
                      include cytokine release syndrome with symptoms like fever
                      and hypotension as well as skin reactions like exanthem and
                      itching. These occur mainly during the first three
                      applications, which is why the dose is gradually increased
                      and the first treatments are administered on an inpatient
                      basis. Tebentafusp thus represents the first effective
                      immunotherapy for patients with metastatic uveal melanoma;
                      however, experience and an inpatient setting are required
                      for treatment induction. Current studies are investigating
                      other goals and tebentafusp’s use in other HLA types as
                      well as adjuvant therapy after treatment of primary uveal
                      melanoma.},
      cin          = {HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)HD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1007/s11654-025-00653-0},
      url          = {https://inrepo02.dkfz.de/record/301484},
}